Holder | Position | Change | Date | |
---|---|---|---|---|
No active short positions |
Holder | Position | Change (%) | Date | |
---|---|---|---|---|
WorldQuant LLC | 0.47% | 12-Mar-2018 | View History | |
WorldQuant LLC | 0.5% | 05-Mar-2018 | View History | |
WorldQuant LLC | 0.49% | 22-Feb-2018 | View History | |
WorldQuant LLC | 0.5% | 21-Feb-2018 | View History | |
WorldQuant LLC | 0.49% | 19-Feb-2018 | View History | |
WorldQuant LLC | 0.51% | 14-Feb-2018 | View History | |
Darwin Strategic Limited | 0% | 14-Oct-2013 | View History | |
Darwin Strategic Limited | 0.91% | 08-Oct-2013 | View History | |
Darwin Strategic Limited | 0.87% | 03-Oct-2013 | View History | |
Darwin Strategic Limited | 0.94% | 01-Oct-2013 | View History | |
Darwin Strategic Limited | 1.04% | 27-Sep-2013 | View History | |
Darwin Strategic Limited | 0.76% | 25-Sep-2013 | View History | |
Darwin Strategic Limited | 0.6% | 24-Sep-2013 | View History | |
Darwin Strategic Limited | 0.54% | 23-Sep-2013 | View History |
mmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France
IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.